Rapamune
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Kidney Diseases
Conditions
Polycystic Kidney Diseases
Trial Timeline
Oct 1, 2006 → Dec 1, 2014
NCT ID
NCT00286156About Rapamune
Rapamune is a phase 1/2 stage product being developed by Pfizer for Polycystic Kidney Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00286156. Target conditions include Polycystic Kidney Diseases.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00044720 | Approved | Completed |
| NCT01853423 | Phase 1 | Completed |
| NCT00286156 | Phase 1/2 | Completed |
| NCT00195481 | Approved | Completed |
| NCT00470665 | Phase 3 | Completed |
Competing Products
20 competing products in Polycystic Kidney Diseases